NCT05765175 - Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT) | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

April 21, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2030

Conditions

Tachycardia, Ventricular

Interventions

DEVICE

Varian Cardiac Radioablation (CRA)

Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.

PROCEDURE

Catheter Ablation (CA)

Subjects randomized to the CA arm will be treated according to a uniform CA protocol.

Trial Locations (10)

15260

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

19104

RECRUITING

University of Pennsylvania, Philadelphia

29425

RECRUITING

Medical University of South Carolina, Charleston

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

43210

RECRUITING

The Ohio State University, Columbus

55905

RECRUITING

Mayo Clinic, Rochester

63110

RECRUITING

Washington University, St Louis

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

06102

RECRUITING

Hartford Hospital, Hartford

02115

RECRUITING

Brigham & Women's Hospital, Boston

All Listed Sponsors

lead

Varian, a Siemens Healthineers Company

INDUSTRY